Clinical Trial: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Lesigercept in Adult Patients with Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines (CLEAR) (China)

China, Aug. 27 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Lesigercept in Adult Patients with Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines (CLEAR)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130938

Registration Time: 2026/08/26

Type: Interventional study

Primary Sponsor: Dematology Hospital of Southern Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=319232

Published by HT Digital Content Services with permission from Health ...